Form 8-K - Current report:
SEC Accession No. 0001641172-25-006227
Filing Date
2025-04-25
Accepted
2025-04-25 16:33:58
Documents
15
Period of Report
2025-04-21
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44450
2 ex3-1.htm EX-3.1 137999
  Complete submission text file 0001641172-25-006227.txt   432556

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE tvgn-20250421.xsd EX-101.SCH 3814
4 XBRL DEFINITION FILE tvgn-20250421_def.xml EX-101.DEF 26690
5 XBRL LABEL FILE tvgn-20250421_lab.xml EX-101.LAB 36843
6 XBRL PRESENTATION FILE tvgn-20250421_pre.xml EX-101.PRE 25314
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 6094
Mailing Address 15 INDEPENDENCE BOULEVARD, SUITE 410 WARREN NJ 07059
Business Address 15 INDEPENDENCE BOULEVARD, SUITE 410 WARREN NJ 07059 646-807-8832
Tevogen Bio Holdings Inc. (Filer) CIK: 0001860871 (see all company filings)

EIN.: 981597194 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41002 | Film No.: 25874687
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)